 LA JOLLA, Calif., July 21, 2021 GLOBE NEWSWIRE -- Artelo Biosciences, Inc. NASDAQ: ARTL , a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that Ladenburg Thalmann Co. Inc. will host an RD showcase focused on the Phase 1b2a Cancer Appetite Recovery Study CAReS, evaluating the Companys lead drug candidate, ART27.13. The webinar will be hosted by Michael Higgins, Managing Director and Senior Biopharmaceutical Equity Research Analyst on July 28th, 2021 at 1pm EDT10am PDT. This event will include the lead investigator on the CAReS study, Barry Laird, PhD, a Senior Clinical Consultant of Palliative Medicine at St Columbas Hospice Care in Edinburg, UK. Among a number of key topics, Dr. Laird will be discussing the etiology of anorexia and the accompanying challenges of effectively treating anorexia. 